Good for Business, Lithuania, Medicine, Technology
International Internet Magazine. Baltic States news & analytics
Friday, 19.04.2024, 04:13
Lithuania's Sicor Biotech boosts sales to US in 2015
BC, Vilnius, 22.07.2016.
Print version
Print versionLithuania's leading biopharmaceutical manufacturer Sicor Biotech, which is controlled by the international generic drugs producer Teva, posted a net profit of 87.018 mln euros for 2015, more than a two-fold increase from 41.171 mln euros in 2014, reports LETA/BNS.
 |
|---|
Annual revenue rose by 30.3 % to 191.791 mln euros, the company said in its 2015 annual report filed with the Center of Registers.
"The sales growth was primarily due to increased sales to the US markets," it said.
Sicor Biotech last year had an average workforce of 219 people, slightly up from 215 in 2014, not including the employees of its Latvian and Estonian units.
Dutch-registered Gatio Investments, which is part of Israel's Teva Pharmaceutical Industries Group, owns 100 % of shares in Sicor Biotech.
«The Baltic Course» Is Sold and Stays in Business!
